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Abstract
Introduction: Calcitonin gene-related peptide is an important vasodilator. It plays an important role in the metabolism of chewing muscles. 
The aim of the study was to evaluate the plasma level of CGRP in patients with myofascial pain (RDC/TMD Ia) and myofascial pain with 
limited opening (RDC/TMD Ib) before and after occlusal splint therapy (Michigan splint).
Material and methods: A randomised trial was performed including 39 patients (males = 3, females = 36). Blood samples were taken 
from the external jugular vein (JUG) and cubital vein (CUB) before and after 30 days of occlusal splint therapy. Plasma levels of CGRP 
were measured with ELISA KIT for Human Calcitonin Gene Related Peptide (CGRP) 96T (USCNK Business Co. Ltd.).
Results: The results of the study show that the plasma CGRP level was higher in the external jugular vein (JUG1 = 5.07pg/mL 
[SD = 1.99]) than in cubital vein (CUB1 = 4.3 pg/mL [SD = 1.6]). After 30 days of the occlusal splint therapy the levels in both veins in-
creased: JUG2 = 6.07 pg/mL (SD = 2.19), and CUB2 = 4.9 pg/mL (SD = 1.4). The CGRP plasma level increase was statistically significant 
only in the external jugular vein (JUG) (p < 0.05). Statistically significant pain intensity reduction was observed: VAS1 = 5.4 (SD = 2.08) 
decreased to VAS2 = 1.7 (SD = 2.07) after splint therapy (p < 0.05).
Conclusions: Venepuncture of an external jugular vein is more precise, than venepuncture of a cubital vein in evaluating CGRP plasma 
level changes in patients with TMD. (Endokrynol Pol 2017; 68 (3): 326–331)
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Streszczenie
Wstęp: Peptyd pochodny genu kalcytoniny jest ważną substancja naczynio-rozkurczową. Odgrywa ważną role w metabolizmie mię-
śni żucia. Celem pracy była ocena stężenia osoczowego CGRP u pacjentów z bólem mięśniowo-powięziowym (RDC/TMD Ia) oraz z 
bólem mięśniowo-powięziowym z ograniczonym odwodzeniem (RDC/TMD Ib), przed i po terapii szyną okluzyjną (Szyna Michigan).
Materiał i metody: Przeprowadzono badanie randomizowane, do którego włączono 39 pacjentów (mężczyźni = 3, kobiety = 36). Próbki 
krwi pobrano z żyły szyjnej zewnętrznej (JUG) oraz z żyły odłokciowej (CUB), przed leczeniem i po 30 dniach stosowania szyny oklu-
zyjnej. Stężenie neuropeptydu CGRP oceniano za pomocą zestawu ELISA KIT for Human Calcitonin Gene Related Peptide (CGRP) 96T 
(USCNK Business Co. Ltd.).
Wyniki: Stwierdzono, że stężenie neuropeptydu CGRP było wyższe w materiale pobranym z żyły szyjnej zewnętrznej JUG1 = 5,07 pg/ml 
(SD = 1,99), niż w materiale pobranym z żyły odłokciowej CUB1 = 4,3 pg/ml (SD = 1,6). Po 30 dniach terapii szyną okluzyjną średnie 
stężenie CGRP w obu grupach CUB i JUG wzrosły: JUG2 = 6,07 pg/ml (SD = 2,19) i CUB2 = 4,9 pg/ml (SD = 1,4). Wzrost stężenia CGRP 
w osoczu krwi był istotny statystycznie jedynie w materiale pobranym z żyły szyjnej zewnętrznej (JUG) (p < 0,05). Zaobserwowano także 
istotną statystycznie redukcję natężenia dolegliwości bólowych w skali VAS: VAS1 = 5,4 (SD = 2,08) redukcja do VAS2 = 1,7 (SD = 2.07), 
po przeprowadzonej szynoterapii (p < 0,05).
Wnioski: Wenopunkcja żyły szyjnej zewnętrznej dostarcza bardziej precyzyjnych pomiarów stężenia neuropeptydu CGRP w osoczu 
niż wenopunkcja żyły odłokciowej, u pacjentów z bólową postacią dysfunkcji narządu żucia. (Endokrynol Pol 2017; 68 (3): 326–331)
Słowa kluczowe: szyna okluzyjna, zewnętrzna żyła szyjna, żyła łokciowa, wenopunkcja, TMD, CGRP
The source of funding was the Silesian Medical University in Katowice, Poland, for the development of the Department of TMD and 
Orthodontics (KNW-2-017/N/4/K).
Introduction
Calcitonin gene-related peptide is a neuroinflamma-
tory molecule promoting nociceptive and neuroim-
mune responses [1]. It was recently implicated in TMD 
(Temporomandibular Disorders) pathophysiology, with 
chronic muscle pain [2]. CGRP (Calcitonin gene-related 
peptide) was first discovered by Amara in 1982 in the 
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thyroid tissue of aging rats [3]. A human form of CGRP 
was first isolated from medullary thyroid carcinomas. 
Two isoforms of CGRP have been discovered (α CGRP, 
ß CGRP), but the ß CGRP is poorly understood [3]. 
Human α CGRP is primarily located in unmyelinated, 
small-diameter sensory C fibres, commonly found in 
close contact with the vasculature, especially the arterial 
side. Vasodilator activity of CGRP was first described by 
Brain in 1985, who characterised it as the most potent 
microvascular vasodilator [4]. An intradermal injec-
tion of CGRP was sufficient to induce erythema and 
increase blood flow in that area [3]. Small doses injected 
into human skin produce an erythema that lasts for 5–6 
hours [4]. The microvasculature responds strongly to 
the CGRP: its potency is 10-fold greater than the pros-
taglandins and 100–1000 times greater than other classic 
vasodilators. Intravenous CGRP administration causes 
facial flushing. Higher doses of CGRP cause skin red-
ness, lasting for several hours, and even hypotension. 
CGRP delivered intravenously causes ionotropic and 
chronotropic heart effects. The CGRP is released from 
activated trigeminal sensory nerves, dilates intracranial 
and extracranial blood vessels, and centrally modulates 
vascular nociception [5].
Endogenous CGRP promotes tumour-associated 
angiogenesis and tumour growth. Another recent study 
supports the cardioprotective role of CGRP against 
ischaemia/reperfusion injury [6]. Circulating levels of 
CGRP are reduced in patients with hypertension [7]. 
After CGRP receptors activation nitric oxide (NO) is 
synthesised and vasodilation takes place. It was also 
observed that the effect of CGRP on microcirculation of 
specific tissues (specific sensitivity) is much more inten-
sive that in the entire circulation. That was the reason 
for stating the hypothesis in our study: to find out if the 
CGRP plasma level is the same in the external jugular 
vein and the cubital vein. The level of this neuropeptide 
decreases with age. Mice treated with CGRP receptor 
antagonist presented a decrease in pain duration and 
pain intensity [2]. 
This study is a continuation of previous research: 
“CGRP plasma level changes in patients with tempo-
romandibular disorders, treated with occlusal splints: 
a randomised clinical trial”, performed in 2014. The aim 
of this study was to evaluate the plasma level changes of 
CGRP (in patients with TMD/RDC Ia and Ib- Research 
Diagnostic Criteria for Temporomandibular Disorders, 
after an occlusal splint therapy) and to compare CGRP 
plasma levels between the external jugular vein and 
cubital vein. Cubital vein venepuncture is much easier 
to perform and less stressful for the patient. If CGRP 
plasma levels were comparable in both samples, it 
would be easier and much more comfortable for a pa-
tient to participate in an experimental study. 
Material and methods
A randomised clinical trial was performed including 
105 patients. Of these, 66 patients were excluded for the 
following reasons: 30 of them did not match inclusion 
criteria, such as RDC/TMD Ia or Ib diagnosis, bruxism 
symptoms, or agreement to use a splint [8] — a Michigan 
splint was produced for the upper arch in each patient; 
in 26 patients venepuncture of the cubital vein (CUB) or 
external jugular vein (JUG) was impossible to perform 
twice (before or after the occlusal splint therapy); and 
10 patients did not return for follow-up visits. Thirty-
nine patients were enrolled to the study (women = 36 
and men = 3), aged 19–70 years (average = 46 years). 
Patients were examined using the RDC/TMD clinical and 
physical examination form [8]. One physician enrolled 
participants in the study and another one assigned them 
to the interventions. The main inclusion criteria were: 
positive RDC/TMD Ia or Ib, patient’s agreement to par-
ticipate in the study and to perform two venepunctures. 
Blood samples were taken from the external jugular vein 
and cubital vein during the first visit and after 30 days 
of splint therapy. If the myofascial pain was equal on 
both sides, we preferred the right jugular vein. Patients 
were in a supine position on a dental unit chair in the 
treatment room when the physician performed the ve-
nepuncture. The study was approved by the Bioethical 
Committee of the Silesian Medical University (document 
number KNW/0022/KB1/104/I/14.)
Exclusion criteria were: anticoagulation treatment, 
platelet or coagulation disorders, primary headaches, 
ophthalmological, neurological, or cardiovascular 
diseases (with hypertension), head traumas in the 
past six months, secondary headaches, and trigeminal 
neuralgias. 
Myalgia (RDC/TMD Ia) and reduction of mouth 
opening (RDC/TMD Ib) were indications for preparing 
occlusal appliances, which patients were given to use 
during sleep for one month (30 days). Blood samples 
were collected twice (on the first visit: JUG1, CUB1, 
and after 30 days of splint therapy: JUG2, CUB2) in 
each patient, from the external jugular vein (JUG) and 
cubital vein (CUB). 
CGRP plasma levels were measured with ELISA KIT 
for Human Calcitonin Gene-Related Peptide (CGRP) 
96T (USCNK Business Co. Ltd.). Data collected during 
biochemical analysis were noted in Excel files. The re-
sults were analysed with Statistica 7.0 for each group, 
and Wilcoxon Test analysis was performed (p = 0.05).
Results
The results of the study show that the plasma CGRP 
level was higher in the external jugular vein JUG1 = 
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5.07 pg/mL than in the cubital vein CUB1 = 4.3 pg/mL, 
but an increase in CGRP level was observed in each 
group. After 30 days of the occlusal splint therapy, levels 
in both veins changed and were elevated: JUG2 = 6.07 
pg/mL and CUB2 = 4.9 pg/mL. In the external jugular 
vein (JUG) an increase of CGRP level was statistically 
relevant, but in the cubital vein (CUB) it was not statis-
tically relevant. In the present study we provide data 
suggesting that the CGRP plasma level is comparable 
in the cubital vein and in the external jugular vein, but 
higher CGRP levels are marked in the external jugular 
vein. The venepuncture of an external jugular vein 
provides blood samples of higher CGRP concentration. 
Comparison of CGRP plasma level changes in 
cubital vein before and after a splint therapy
The CGRP plasma level changes in a cubital vein (Fig. 1) 
before and after a splint therapy in the experimental 
group were statistically irrelevant, p = 0.054.
Comparison of the CGRP plasma level changes 
in external jugular vein before and after splint 
therapy
The CGRP plasma level changes in an external jugular 
vein (Fig. 2) before and after a splint therapy in experi-
mental group were statistically relevant, p < 0.05 (p = 
0.000076).
Comparison of the pain intensity changes in VAS 
(Visual analogue scale) before and after a splint 
therapy
The pain intensity reduction after splint therapy in the 
experimental group (Fig. 3) was statistically relevant, 
p < 0.05(p = 0.0).
In both the JUG (external jugular vein) and CUB 
(cubital vein) an increase in CGRP concentration was 
observed; it was statistically relevant for the external 
jugular vein (JUG1 = 5.07 and JUG2 = 6.07 pg/mL). 
For the cubital vein (CUB1 = 4.3 pg/mL and CUB2 = 
4.9 pg/mL) CGRP plasma level changes were statisti-
cally insignificant (p > 0.05). The pain intensity reduc-
tion after splint therapy in the experimental group 
was statistically significant: VAS1 = 5.4 (SD = 2.08) 
decreased to VAS2 = 1.7 (SD = 2.07), (p < 0.05). The 
results of our previous study with CGRP are similar. The 
same tendencies in plasma CGRP levels are observed 
in both trials. 
DISCUSSION
CGRP is released after stimulation of TRPV1 (Transient 
Receptor Potential Ion Channels) receptors and TRPA 
(Transient Receptor Potential Ion Channels) receptors, 
by capsaicin, noxious heat, and most importantly in our 
Figure 1. CGRP plasma level changes in cubital vein before and 
after splint therapy
Rycina 1. Zmiany stężenia osoczowego CGRP, w żyle odłokciowej, 
przed i po terapii szyną okluzyjną
Figure 2. CGRP plasma level changes in external jugular vein 
before and after splint therapy
Rycina 2. Zmiany stężenia osoczowego CGRP, w żyle szyjnej 
zewnętrznej, przed i po terapii szyną okluzyjną
Figure 3. Pain intensity before and after splint therapy
Rycina 3. Nasilenie bólu przed i po terapii szyną okluzyjną
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study, by the high concentration of protons (lowered 
environmental pH) [7]. Myalgia is often accompanied 
by anaerobic muscle metabolism and accumulation 
of lactate. Glycolysis provides anaerobic energy in 
extremely hard or long lasting muscle activity. The 
concentration of lactate is rising then, and lowered en-
vironmental pH appears [9]. In our study the patients 
suffered from muscle pain. The CGRP plasma level was 
expected to be elevated. Average CGRP plasma levels in 
the present study were: CUB1 = 4.3 pg/mL (1.14 pM), 
CUB2 = 4.9 pg/mL (1.3 pM) and JUG1 = 5.07 (1.35 pM), 
JUG2 = 6.07 pg/mL (1.6 pM). Physiological plasma levels 
of CGRP in humans are usually in the picomolar range, 
and this low level is attributed to overspill from the 
release site to systemic circulation. Elevated concentra-
tions of CGRP are observed in patients with migraine 
(345 pg/mL = 92 pM), comparing to healthy patients 
(150 pg/mL = 40 pM). Cernuda-Morollon determined 
CGRP plasma levels in patients with migraine in the 
right antecubital vein using an ELISA kit. In patients 
with chronic migraine the average CGRP levels were 
74.9 pg/mL, compared to healthy women 33.74 pg/mL. 
In patients with episodic migraine 46.37 pg/mL and with 
cluster headache 45.87 pg/mL [10]. Those levels of CGRP 
were higher, compared to our study. Sarchielli also 
confirmed previous findings of an increase in calcitonin 
gene-related peptide in internal jugular venous blood of 
migraine without aura [11]. In Reynaud’s Phenomenon 
there is a decreased level of CGRP in digital circulation. 
Patients receiving CGRP intravenously at room tem-
perature have a proper digital vasoconstriction. At 5°C 
the effect of CGRP administration is poor [3].
Appelgren reported the important role of CGRP 
in TMD in 1995 [12]. Vause and Durham stated that 
CGRP is released from neurons of the trigeminovas-
cular system and promotes trigeminal ganglion inflam-
mation, which mediates peripheral sensitisation and 
temporomandibular disorders [13]. Kopp reported the 
connection between an anterior open bite and high 
levels of CGRP [14]. 
There are studies comparing CGRP levels in the ex-
ternal jugular vein and the radial or cubital vein [15, 16]. 
The aim of the study was evaluation of local and periph-
eral CGRP plasma concentration in patients with TMD. 
Blood samples collected from the cubital vein were less 
useful than those from the external jugular vein because 
of the lower CGRP level. Ashina and Bendtsen also 
observed elevated CGRP levels in blood collected from 
the cubital vein [15]. Tvedskov and Ashina found no 
difference between CGRP levels in the cubital vein and 
the external jugular vein in patients with migraines [16]. 
Frieberg compared CGRP and other neuropeptides lev-
els in migraineurs by repeated blood samples obtained 
from the carotid artery and the internal jugular vein and 
found no detectable changes. All migraineurs had an 
overall elevated mean CGRP value compared to control 
values [17]. The ELISA KIT used in our study was sensi-
tive enough to detect CGRP in the jugular vein and in 
the cubital vein in TMD patients. Elevated CGRP plasma 
levels, in external jugular vein and in cubital vein, were 
found after 30 days with occlusal splints, accompanied 
by pain relief. A statistically significant reduction in 
pain intensity based on the VAS scale was observed and 
patients’ health improved as well. Venepuncture was 
one of our trial limitations because the procedure was 
stressful for the patients, and not every patient decided 
to participate in the trial. Another limitation was the 
short period of time between the collection of the first 
and second blood samples. The samples used for meas-
urements can only be frozen at –70°C for one month. In 
1999, Parlapiano evaluated CGRP plasma levels and ET-1 
plasma levels in normal subjects and reported that the 
mean plasma CGRP level was 42.8 pg/mL. The plasma 
concentration was measured using a radioimmunoassay 
kit (Peninsula Labs), but the authors did not mention 
which blood vessels the blood samples were collected 
from [18]. Elevated levels of CGRP were also analysed 
by Joyce, who found that in healthy patients, the level 
was 2.0 ± 0.3 pg/mL and that in patients with sepsis, 
the level was 14.9 ± 3.2 pg/mL [19]. CGRP plasma levels 
in this study are similar to our results. These findings 
contribute to a decreased vascular resistance in dilatory 
states and increased cardiac output in septic states. The 
same vascular dilatation may occur in masticatory mus-
cles of patients with TMD. 
Muscle pain causes release of neuropeptides, which 
initiate and maintain neurogenic inflammation. We 
know that 5-HT (5-hydroxytryptamine, serotonin) and 
PGE2 (prostaglandin 2 receptor) are involved in the 
development of pain and hyperalgesia or allodynia 
of the masseter muscle in patients with fibromyalgia, 
whereas myofascial pain seems to be modulated by 
other, as yet unknown, mediators. Interaction between 
the peripheral nervous system, the immune system, 
and local cells is probably of great importance for the 
modulation of pain and inflammation in the TMJ (tem-
poromandibular joint) and orofacial musculature [14]. 
Peripheral and central sensitisation leads to hyperal-
gesia and allodynia. Cady injected CGRP into the TMJ 
capsule of rats and observed the inflammation process 
and sensitisation [20]. Sato concluded that CGRP may 
play an important role in the pain mechanism and 
that CGRP elevated levels may be correlated with joint 
pain [21]. Bick demonstrated that CGRP causes calcium 
mobilisation in skeletal muscle cells. High levels of 
CGRP caused continuous tetanus, which could be the 
reason for muscle-tension headaches. Bick conducted 
different studies with various aspects of muscle sore-
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ness, exercise, and repair [22]. Homonko observed an 
increased number of CGRP+ motoneurons in muscles 
after physiological neuromuscular activity [23, 24]. 
The exercise regimen may result in damage to the 
muscle tissue, thereby initiating repair and regenera-
tive mechanisms [25]. This repair process may be the 
reason for the elevated concentration of CGRP in our 
experimental group of patients with TMD. Jonhagen 
detected increased CGRP levels after eccentric exercise 
in healthy subjects, which may reflect tissue regenera-
tion [24]. Eccentric contraction can occur after muscles 
are stretched during contraction [25]. CGRP muscle 
levels were estimated in vivo by microdialysis followed 
by radioimmunoassay and were found to be increased 
a few days after eccentric exercise, and this may also be 
the reason for the elevated CGRP plasma levels in our 
experimental group of patients. The eccentric exercise 
performed in the Jonhagen study may be similar to the 
masseter and temporalis muscle exercises with occlusal 
splints in our experimental group [24]. According to 
Dessem the masseter muscle has a limited ability to 
repair itself after injury and a tendency to undergo 
apoptosis [26]. Dessem also presented evidence that 
masticatory muscles do not adapt to repeated injury 
(bruxism), such as that occurring in hindlimb muscles; 
therefore, masticatory muscles are more susceptible to 
injuries and chronic muscle pain.
Mc Daniel noticed that blood flow in muscles is al-
tered by changes in muscle length: the longer and more 
relaxed the muscle is, the higher the blood flow [27]. 
Occlusal splints change the vertical dimension and 
stretch masseter and temporal muscles. The altered 
muscle length decreases muscle tone and produces 
masticatory muscle relaxation, which is probably the 
reason for increased muscular blood flow. These find-
ings suggest that CGRP may participate in muscle 
contraction and stretching. Cerebral blood vessels are 
innervated by sensory nerves that store several neu-
rotransmitters. In primary headaches there is a clear 
association between head pain and the release of the 
neuropeptide CGRP [28–31]. Muscle spasm may also be 
treated successfully with botulinum toxin type A(BTX-A) 
by local muscle injection, as reported by Guarda-Nardini 
in an investigation of its efficacy in reducing myofas-
cial pain symptoms in bruxers [32]. Muscle stretching 
with occlusal splints increases CGRP release from the 
trigeminovascular system, but BTX-A produces muscle 
paralysis and decreases the CGRP concentration. An 
interesting observation in our study is that during the 
time of elevated CGRP plasma concentration, there was 
a negative correlation between the VAS scale and the 
CGRP plasma level concentration. A similar situation 
was observed by Ashina, who indicated that ongoing 
activity in sensory neurons in cranial muscles may 
result in plasma CGRP level changes in patients with 
chronic headache. Eight patients had higher CGRP 
plasma levels in the delayed headache-free period. 
However, a small number of patients were enrolled in 
this study, and the CGRP plasma levels in the cranial 
and peripheral circulation may be undetectable [3]. 
Eccentric muscle contraction and rapid stretching pro-
duces scattered myofibres and intramuscular plasma 
extravasation [25]. CGRP vasodilates blood vessels in 
muscle tissue and mediates neurogenic inflammation. 
In his study Donnerer noted an important regulatory 
function of neuropeptides such as CGRP and substance 
P in healing processes [33]. 
Conclusions
The CGRP plasma level is increased in the external 
jugular vein and in the cubital vein after 30 days of splint 
therapy in patients with TMD. The mechanism of CGRP 
accumulation is not well known. In our study the plasma 
level of CGRP changed in both sample collections (JUG 
and CUB), but it was statistically relevant only in sam-
ples collected from the external jugular vein (JUG). The 
concentration of neuropeptide CGRP is detectable in 
the cubital vein, but the increase that we observed was 
not statistically important. For more precise results, it is 
better to collect samples from the external jugular vein 
rather than from the cubital vein. This neuropeptide is 
probably implicated in muscle healing and may serve 
multiple functions, including muscle repair. This study 
shows that CGRP is involved in muscle contractility 
and the myofibre repair process in patients with TMD.
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Table I. Median values of the CGRP plasma level before (1) 
and after 30 days (2) of occlusal splint therapy
Tabela I. Średnie wartości osoczowego stężenia CGRP przed 
(1) oraz 30 dni po (2) szynoterapii szyną okluzyjną
Before a splint 
therapy (1)
JUG V. CUB V. VAS
5,07 pg/mL 4,3 pg/mL VAS1 = 5,4
After a splint 
therapy (2)
6,07 pg/mL: 4,9 pg/mL VAS2 = 1,7
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